StreetInsider.com News Articles

Zymeworks ZW191 shows 64.5% response rate in ovarian cancer trial

Sat, 24 Oct 2026 02:30:15 -0400

Zymeworks Inc. (Nasdaq: ZYME) presented Phase 1 clinical data for ZW191, its folate receptor alpha (FRα)-targeting antibody-drug conjugate, at the European Society for Medical Oncology Congress 2026 in Madrid, Spain, according to a company statement.

The data, drawn from 80 patients with platinum-resistant ovarian cancer, showed a confirmed objective response rate of 64.5% at the 6.4 mg/kg dose and 55.3% at the 9.6 mg/kg dose among response-evaluable patients with high-grade serous disease. Disease control rates were 100% and 92.1%, respectively.

Patients had received a median of four prior lines of therapy, with 45% having received five or more. Median follow-up was seven

Zymeworks ZW191 shows 64.5% response rate in ovarian cancer trial

Sat, 24 Oct 2026 02:30:15 -0400

Zymeworks Inc. (NASDAQ: ZYME) presented Phase 1 clinical data for its antibody-drug conjugate ZW191 at the European Society for Medical Oncology Congress 2026 in Madrid, Spain, showing response rates in patients with platinum-resistant ovarian cancer.

The data, drawn from 80 heavily pretreated patients randomized to receive ZW191 at either 6.4 mg/kg or 9.6 mg/kg every three weeks, showed confirmed objective response rates of 64.5% and 55.3%, respectively, among response-evaluable patients with high-grade serous platinum-resistant ovarian cancer. Disease control rates were 100% at 6.4 mg/kg and 92.1% at 9.6 mg/kg.

Across folate receptor alpha expression levels in high-grade serous patients, confirmed objective response

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

Sat, 24 Oct 2026 02:30:00 -0400

ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha (FRα) expression levels
Confirmed objective response rates (cORR) of 64.5% at the 6.4 mg/kg dose in patients with high-grade serous platinum-resistant ovarian cancer
Median duration of response not yet reached at either dose level at median 7 months follow-up, with six-month progression-free survival rate of 61% in both groups
Favorable tolerability profile, particularly at 6.4 mg/kg, supports continued clinical development in partnership or through a strategic collaboration
Conference call with Zymeworks

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026

Sat, 24 Oct 2026 02:30:00 -0400

ZW191 demonstrates compelling anti-tumor activity in heavily pretreated patients with platinum-resistant ovarian cancer across folate receptor alpha (FRα) expression levels
Confirmed objective response rates (cORR) of 64.5% at the 6.4 mg/kg dose in patients with high-grade serous platinum-resistant ovarian cancer
Median duration of response not yet reached at either dose level at median 7 months follow-up, with six-month progression-free survival rate of 61% in both groups
Favorable tolerability profile, particularly at 6.4 mg/kg, supports continued clinical development in partnership or through a strategic collaboration
Conference call with Zymeworks

Zymeworks (ZYME) PT Raised to $52 at Jefferies

Fri, 23 Oct 2026 14:42:34 -0400

Jefferies analyst Akash Tewar raised the price target on Zymeworks (NASDAQ: ZYME) to $52.00 (from $50.00) while maintaining a Buy rating.
The analyst comments "ZYME & Roche entered an exclusive global license / collaboration agreement for ZW209 (DLL3 trispecific TCE) where ZYME will receive $55M upfront, $40M upon Ph1b trial initiation, and potential for up to $718M in additional milestones + co is eligible for tiered high-single-digit to mid-teen royalties. We think this deal fits directly within ZYME's new strategic approach to become a royalty-driven co w/ in-house R&D capabilities & see this as ~$2/sh NPV +'ve Bottom line: ZYME and

Zymeworks (ZYME) PT Raised to $52 at Jefferies

Fri, 23 Oct 2026 14:42:34 -0400

Jefferies analyst Akash Tewar raised the price target on Zymeworks (NASDAQ: ZYME) to $52.00 (from $50.00) while maintaining a Buy rating.
The analyst comments "ZYME & Roche entered an exclusive global license / collaboration agreement for ZW209 (DLL3 trispecific TCE) where ZYME will receive $55M upfront, $40M upon Ph1b trial initiation, and potential for up to $718M in additional milestones + co is eligible for tiered high-single-digit to mid-teen royalties. We think this deal fits directly within ZYME's new strategic approach to become a royalty-driven co w/ in-house R&D capabilities & see this as ~$2/sh NPV +'ve Bottom line: ZYME and

Zymeworks stock surges on $813M Roche licensing deal

Fri, 23 Oct 2026 09:05:42 -0400

Investing.com -- Zymeworks Inc (NASDAQ:ZYME) shares rose 5.5% in premarket trading Friday following the announcement of a global license and collaboration agreement with Roche for ZW209, a T cell engager targeting DLL3, in a deal worth up to $813 million.

Under the agreement, Zymeworks will receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial. The company is also eligible for up to $718 million in additional development, commercial and sales-based milestone payments, plus tiered high single-digit to mid-teen royalties on global net sales protected by patents extending into the

Zymeworks stock surges on $813M Roche licensing deal

Fri, 23 Oct 2026 09:05:42 -0400

Investing.com -- Zymeworks Inc (NASDAQ:ZYME) shares rose 5.5% in premarket trading Friday following the announcement of a global license and collaboration agreement with Roche for ZW209, a T cell engager targeting DLL3, in a deal worth up to $813 million.

Under the agreement, Zymeworks will receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial. The company is also eligible for up to $718 million in additional development, commercial and sales-based milestone payments, plus tiered high single-digit to mid-teen royalties on global net sales protected by patents extending into the

Zymeworks stock surges on $813M Roche licensing deal

Fri, 23 Oct 2026 09:05:42 -0400

Investing.com -- Zymeworks Inc (NASDAQ:ZYME) shares rose 5.5% in premarket trading Friday following the announcement of a global license and collaboration agreement with Roche for ZW209, a T cell engager targeting DLL3, in a deal worth up to $813 million.

Under the agreement, Zymeworks will receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial. The company is also eligible for up to $718 million in additional development, commercial and sales-based milestone payments, plus tiered high single-digit to mid-teen royalties on global net sales protected by patents extending into the

Zymeworks stock surges on $813M Roche licensing deal

Fri, 23 Oct 2026 09:05:42 -0400

Investing.com -- Zymeworks Inc (NASDAQ:ZYME) shares rose 5.5% in premarket trading Friday following the announcement of a global license and collaboration agreement with Roche for ZW209, a T cell engager targeting DLL3, in a deal worth up to $813 million.

Under the agreement, Zymeworks will receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial. The company is also eligible for up to $718 million in additional development, commercial and sales-based milestone payments, plus tiered high single-digit to mid-teen royalties on global net sales protected by patents extending into the

Form 8-K Zymeworks Inc. For: Oct 22

Fri, 23 Oct 2026 06:07:00 -0400
si-local-file:///var/storage/secattach/20261023/27224675.html

Zymeworks licenses ZW209 to Roche in deal worth up to $813M

Fri, 23 Oct 2026 06:01:40 -0400

Zymeworks Inc. (NASDAQ: ZYME) announced an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager targeting DLL3, a protein associated with certain cancers including small cell lung cancer.
Under the terms of the agreement, Zymeworks will receive a $55 million upfront payment and a $40 million payment upon initiation of a Phase 1b trial. The company is also eligible for up to $718 million in additional development, commercial, and sales-based milestone payments, along with tiered royalties in the high-single-digit to mid-teen percentage range on global net sales. Patents covering the collaboration extend into the 2040s.
Zymeworks

Zymeworks licenses ZW209 to Roche in deal worth up to $813M

Fri, 23 Oct 2026 06:01:40 -0400

Zymeworks Inc. (NASDAQ: ZYME) announced an exclusive global license and collaboration agreement with Roche for ZW209, a trispecific T cell engager targeting DLL3, a protein associated with certain cancers including small cell lung cancer.
Under the terms of the agreement, Zymeworks will receive a $55 million upfront payment and a $40 million payment upon initiation of a Phase 1b trial. The company is also eligible for up to $718 million in additional development, commercial, and sales-based milestone payments, along with tiered royalties in the high-single-digit to mid-teen percentage range on global net sales. Patents covering the collaboration extend into the 2040s.
Zymeworks

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

Fri, 23 Oct 2026 06:00:00 -0400

Zymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 million in additional development, commercial and sales-based milestones
Zymeworks also eligible to receive tiered high-single-digit to mid-teen royalties on global net sales protected by patents extending into 2040’s
Zymeworks will conduct the Phase 1a monotherapy clinical trial of ZW209 in collaboration with Roche
U.S. FDA IND clearance received with additional global regulatory applications planned to support the opening of clinical study sites outside the U.S.
Transaction is subject to the expiration or termination of the waiting

Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3

Fri, 23 Oct 2026 06:00:00 -0400

Zymeworks to receive a $55 million upfront payment and a $40 million payment upon initiation of the Phase 1b trial, with potential for up to $718 million in additional development, commercial and sales-based milestones
Zymeworks also eligible to receive tiered high-single-digit to mid-teen royalties on global net sales protected by patents extending into 2040’s
Zymeworks will conduct the Phase 1a monotherapy clinical trial of ZW209 in collaboration with Roche
U.S. FDA IND clearance received with additional global regulatory applications planned to support the opening of clinical study sites outside the U.S.
Transaction is subject to the expiration or termination of the waiting

Zymeworks names Suzanne Monahan as SVP Commercial for YUPELRI

Mon, 19 Oct 2026 06:00:14 -0400

Zymeworks Inc. (Nasdaq: ZYME) has appointed Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma, effective immediately, according to a company statement.

Monahan will report directly to Kenneth Galbraith, Chair and Chief Executive Officer, and will lead commercial strategy and execution for YUPELRI (revefenacin), a once-daily, nebulized long-acting muscarinic antagonist approved in the U.S. for the maintenance treatment of chronic obstructive pulmonary disease. The appointment follows Zymeworks' acquisition of Theravance Biopharma.

Monahan brings more than 20 years of commercial experience in the pharmaceutical and medical device industries. She most recently served as Senior Vice President at Pacira BioSciences, where

Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

Mon, 19 Oct 2026 06:00:00 -0400

VANCOUVER, British Columbia , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that Suzanne Monahan has been appointed Senior Vice President, Commercial and General Manager, Theravance Biopharma, effective immediately. Reporting directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks, Ms. Monahan will lead Zymeworks’ commercial strategy and execution for YUPELRI® (revefenacin), the first and only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for the maintenance treatment of chronic obstructive pulmonary

Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma

Mon, 19 Oct 2026 06:00:00 -0400

VANCOUVER, British Columbia , Oct. 19, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that Suzanne Monahan has been appointed Senior Vice President, Commercial and General Manager, Theravance Biopharma, effective immediately. Reporting directly to Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks, Ms. Monahan will lead Zymeworks’ commercial strategy and execution for YUPELRI® (revefenacin), the first and only once-daily, nebulized long-acting muscarinic antagonist (LAMA) approved in the U.S. for the maintenance treatment of chronic obstructive pulmonary

Form PRE 14A Zymeworks Inc. For: Dec 15

Fri, 16 Oct 2026 16:15:00 -0400
si-local-file:///var/storage/secattach/20261016/27198123.html

Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

Thu, 15 Oct 2026 06:00:00 -0400

Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026
VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its third quarter 2026 financial results after market close on November 9, 2026.

Consistent with its current practice, Zymeworks does not plan to host a conference call or webcast for its third quarter 2026 financial results. Management looks forward to engaging with the investment community at upcoming events.

Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results

Thu, 15 Oct 2026 06:00:00 -0400

Zymeworks to Report Third Quarter 2026 Financial Results on November 9, 2026
VANCOUVER, British Columbia, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced that management will report its third quarter 2026 financial results after market close on November 9, 2026.

Consistent with its current practice, Zymeworks does not plan to host a conference call or webcast for its third quarter 2026 financial results. Management looks forward to engaging with the investment community at upcoming events.

Form 4 Zymeworks Inc. For: Oct 09 Filed by: Schayowitz Adam

Fri, 09 Oct 2026 18:28:00 -0400
si-local-file:///var/storage/secattach/20261009/27172478.html

Form 144 Zymeworks Inc. Filed by: Schayowitz Adam

Fri, 09 Oct 2026 11:17:00 -0400
si-local-file:///var/storage/secattach/20261009/27170333.html

Zymeworks (ZYME) PT Raised to $34 at Truist Securities

Wed, 07 Oct 2026 07:14:58 -0400
Truist Securities analyst Gregory Renza raised the price target on Zymeworks (NASDAQ: ZYME) to $34.00 (from $32.00) while maintaining a Buy rating.

TD Cowen Reinstates Zymeworks (ZYME) at Buy

Tue, 29 Sep 2026 09:34:02 -0400

TD Cowen analyst Yaron Werber reinstates coverage on Zymeworks (NASDAQ: ZYME) with a Buy rating and a price target of $34.00.
The analyst comments "ZYME closed the Theravance acquisition, underscoring a differentiated whole-company acquisition model that can access embedded commercial, royalty and R&D value. Mgmt expects mid-teens base-case IRR driven by Yupelri (should continue to grow in hospital channel), with multiple potential upside sources. FY26 guidance of $278-292M total revs and $114-128M adjusted EBITDA. Reinstating at Buy, PT $34."
For an analyst ratings summary and ratings history on Zymeworks click here. For more ratings news on Zymeworks click here.
Shares of